Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10766-10770

  Choi, Eunhyun ^a,b   Lee, Chulho ^b   Cho, Misun ^b   Seo, Jeong Jea ^b   Yang, Jee Sun ^b   Oh, Soo Jin ^c   Lee, Kiho ^d   Park, Song Kyu ^d   Kim, Hwan Mook ^e   Kwon, Ho Jeong ^b   Han, Gyoonhee ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Korea University   (South Korea)

^e Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALLYL (4 BROMO BENZYL)CARBAMOYL]PENT 4 ENOIC ACID METHYL ESTER; CARBON; GAMMA LACTAM DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; MOLECULAR DOCKING; MOUSE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; LACTAMS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84870986026     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3009376     Document Type: Article

References (22)

1. Lemoine, M.; Younes, A. Histone deacetylase inhibitors in the treatment of lymphoma Discovery Med. 2010, 10, 462-470
2. Carafa, V.; Nebbioso, A.; Altucci, L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge and patenting of anti-cancer actions Recent Pat. Anti-Cancer Drug Discovery 2011, 6, 131-145
3. Kang, M. R.; Kang, J. S.; Han, S. B.; Kim, J. H.; Kim, D. M.; Lee, K.; Lee, C. W.; Lee, K. H.; Lee, C. H.; Han, G.; Kim, H. M.; Park, S. K. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells Biochem. Pharmacol. 2009, 78, 486-194
4. Yoon, H. C.; Choi, E.; Park, J. E.; Cho, M.; Seo, J. J.; Oh, S. J.; Kang, J. S.; Kim, H. M.; Park, S. K.; Lee, K.; Han, G. Property based optimization of delta-lactam HDAC inhibitors for metabolic stability Bioorg. Med. Chem. Lett. 2010, 20, 6808-6811
5. Kim, H. M.; Lee, K.; Park, B. W.; Ryu, D. K.; Kim, K.; Lee, C. W.; Park, S. K.; Han, J. W.; Lee, H. Y.; Han, G. Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 4068-4070
6. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy Med. Res. Rev. 2005, 25, 261-309
7. Muri, E. M. F.; Nieto, M. J.; Sindelar, R. D.; Williamson, J. S. Hydroxamic acids as pharmacological agents Curr. Med. Chem. 2002, 9, 1631-1653
8. Kavanaugh, S. M.; White, L. A.; Kolesar, J. M. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma Am. J. Health-Syst. Pharm 2010, 67, 793-797
9. Vigushin, D. M.; Ali, S.; Pace, P. E.; Mirsaidi, N.; Ito, K.; Adcock, I.; Coombes, R. C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo Clin. Cancer Res. 2001, 7, 971-976
10. Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knauper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study J. Med. Chem. 1999, 42, 2610-2620
11. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99, 2735-2776
12. Choi, E.; Lee, C.; Park, J. E.; Seo, J. J.; Cho, M.; Kang, J. S.; Kim, H. M.; Park, S. K.; Lee, K.; Han, G. Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 1218-1221
13. Kwon, H. K.; Ahn, S. H.; Park, S. H.; Park, J. H.; Park, J. W.; Kim, H. M.; Park, S. K.; Lee, K.; Lee, C. W.; Choi, E.; Han, G.; Han, J. W. A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells Biol. Pharm. Bull. 2009, 32, 1723-1727
14. Kim, H. M.; Oh, S. J.; Park, S. K.; Han, G.; Kim, K.; Lee, K. S.; Kang, J. S.; Nam, M.; Lee, K. In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum Xenobiotica 2008, 38, 281-293
15. Kim, H. M.; Ryu, D. K.; Choi, Y.; Park, B. W.; Lee, K.; Han, S. B.; Lee, C. W.; Kang, M. R.; Kang, J. S.; Boovanahalli, S. K.; Park, S. K.; Han, J. W.; Chun, T. G.; Lee, H. Y.; Nam, K. Y.; Choi, E. H.; Han, G. Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors J. Med. Chem. 2007, 50, 2737-2741
16. Kim, H. M.; Hong, S. H.; Kim, M. S.; Lee, C. W.; Kang, J. S.; Lee, K.; Park, S. K.; Han, J. W.; Lee, H. Y.; Choi, Y.; Kwon, H. J.; Han, G. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 6234-6238
17. Lee, C.; Choi, E.; Cho, M.; Lee, B.; Oh, S. J.; Park, S. K.; Lee, K.; Kim, H. M.; Han, G. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: Part II Bioorg. Med. Chem. Lett. 2012, 22, 4189-4192
18. Yang, J. S.; Chun, T. G.; Nam, K. Y.; Kim., H. M.; Han, G. Structure-Activity Relationship of Novel Lactam Based Histone Deacetylase Inhibitors as Potential Anticancer Drugs Bull. Korean Chem. Soc. 2012, 33, 2063-2066
19. Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C. E.; Navre, M.; Gangloff, A. R. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N -(2-aminophenyl) benzamides Bioorg. Med. Chem. Lett. 2010, 20, 3142-3145
20. Accelrys Discovery Studio 3.0; Accelrys Software, Inc.: San Diego, 2011.
21. HDAC Fluorescent Activity Assay/Drug Discovery Kit AK-500, BIOMOL International, Inc.: Plymouth Meeting, PA.
22. PreADMET 2.0; BMDRC: Seoul, 2007.